Voyager Therapeutics (FRA:VT6) Growth Rank: 5 (As of Aug. 03, 2026) — 67% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:VT6 Voyager Therapeutics Inc FRA:VT6
54 GF Score
Price €2.61
GF Value €1.44
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Voyager Therapeutics Growth Rank?

Voyager Therapeutics FRA:VT6 +4.16% 54 Growth Rank is 5 as of Aug. 03, 2026, which is 67% above its 10-year median of 3.00. GuruFocus rates FRA:VT6 with a GF Score™ of 54/100 and a GF Value™ of €1.44 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Voyager Therapeutics has the Growth Rank of 5.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Voyager Therapeutics Growth Rank Related Terms

FRA:VT6 vs NERV, DTIL, GLSI: Growth Rank Comparison

For the Biotechnology subindustry, Voyager Therapeutics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyager Therapeutics Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Growth Rank distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Growth Rank falls into.


FRA:VT6
54GF Score
Voyager Therapeutics Inc FRA:VT6
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 5 mean?
Voyager Therapeutics (FRA:VT6) has a Growth Rank of 5 as of Aug. 03, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Voyager Therapeutics and its competitors. This is 67% above median its historical median of 3.00. Over the past decade, Voyager Therapeutics' Growth Rank has ranged from 1.00 to 9.00.
Is Voyager Therapeutics' Growth Rank too high?
Voyager Therapeutics' current Growth Rank of 5 is 67% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. Overall, Voyager Therapeutics has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' Growth Rank compare to NERV and DTIL?
Voyager Therapeutics' Growth Rank of 5 can be compared against companies in the Biotechnology industry. Historically, Voyager Therapeutics' own Growth Rank has ranged from 1.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Voyager Therapeutics and its competitors. Voyager Therapeutics's current Growth Rank is 5, which is 67% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.44, compared to a current price of €2.61 — trading 81% above its estimated fair value. The current Growth Rank is 5, which is 67% above median its 10-year median of 3.00. Voyager Therapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current Growth Rank is 5 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of €2.61 is trading 81% above its estimated GF Value™ of €1.44. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:VT6:

  • Growth Rank: 5 (67% above median its 10-year median of 3.00)
  • GF Value™: €1.44 vs. price of €2.61 (81% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Voyager Therapeutics Business Description

Other Exchanges VYGR:USAVYGR:Mexico
Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
54GF Score

Get the complete analysis for FRA:VT6

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.61
Price
€1.44
GF Value